WHAT'S TISCH? RESEARCH STEM CELL TRIAL NEWS TEAM TISCH GET INVOLVED SEARCH DONATE Saud A. Sadiq, MD, FAAN “Above all, I think the secret to the success of the Tisch MS Research Center is that there is a real and genuine connection between the patients and the doctor that embodies the very best in medicine... true compassion, dedication, humility and knowing that the doctor is indeed honored and privileged to be a healing servant of the patient.” - Dr. Saud A. Sadiq, Director and Chief Research Scientist of the Tisch MS Research Center of New York. Who is Dr. Saud A. Sadiq? Dr. Sadiq, a native of Kenya, is a board-certified neurologist who completed medical school at the University of Nairobi and residency training in Internal Medicine in Kenya and in England. He then completed a residency in Neurology at the University of Texas, where he was elected to the Alpha Omega Alpha Honor Medical Society. From 1988-91, he trained as a research fellow funded by a Dana Fellowship award and an MDA Fellowship in Neuroimmunology at Columbia University in New York. From 1992-98, he was Assistant Professor of Neurology at the Neurological Institute at Columbia University, where he served as Associate Director of the MS Clinical Program. In 1998, he became Director of the MS Research and Treatment Center at St. Luke’s-Roosevelt Hospital in New York. From 2000-2005, he served as Chairman of the Department of Neurology at St. Luke’s-Roosevelt, with faculty appointments at Columbia University and Albert Einstein College of Medicine. His research interests are focused on MS and include investigating the intrathecal oligoclonal B-cell response; exploring the mechanisms of disease progression, biomarker development, and applying stem cell biology to clinical use. Clinically, Dr. Sadiq is an internationally acknowledged expert in MS, receiving numerous awards for his research and clinical activities. He has been an invited guest speaker nationally and internationally at numerous conferences and has more than 100 publications. He is among a select few MS specialists who has a full time clinical practice and is able to combine it with directing a productive laboratory-based research program. Included in the following Castle Connolly publications and/or partner publications: America's Top Doctors: 14th Edition, 13th Edition America's Top Doctors: 2020, 2019, 2018, 2017, 2016 Top Doctors: New York Metro Area: 18th Edition, 17th Edition, 16th Edition, 15th Edition, 14th Edition Top Doctors New York Metro Area: 2020, 2019, 2018, 2017, 2016 New York Magazine: Best Doctors Issue: 2020, 2019, 2018, 2017, 2016, 2014, 2013,1999 (Hall of Fame Issue), 1996 SELECTED PUBLICATIONS Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis Adenosine A2A receptor agonist ameliorates EAE and correlates with Th1 cytokine-induced blood brain barrier dysfunction via suppression of MLCK signaling pathway Fetuin-A deficiency protects mice from Experimental Autoimmune Encephalomyelitis (EAE) and correlates with altered innate immune response. Biomarkers of multiple sclerosis: current findings. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis. Stem cell therapy in multiple sclerosis: a future perspective Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice. Inhibition of hyaluronan (HA) synthesis protects against CNS autoimmunity and increases CXCL12 expression in the inflamed CNS CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice Cerebrospinal fluid derived from progressive multiple sclerosis patients promotes neuronal and oligodendroglial differentiation of human neural precursor cells in vitro Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab Cerebrospinal Hepatocyte Growth Factor Levels Correlate Negatively With Disease Activity in Multiple Sclerosis Characterization of Autologous Mesenchymal Stem Cell-Derived Neural Progenitors as a Feasible Source of Stem Cells for Central Nervous System Applications in Multiple Sclerosis Use of intrathecal clonidine in patients with multiple sclerosis or spastic paraparesis Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalitis Clinical and Pathological Effects of Intrathecal Injection of Mesenchymal Stem Cell-Derived Neural Progenitors in an Experimental Model of Multiple Sclerosis Mesenchymal Stem Cells Enhance the Engraftment and Myelinating Ability of Allogeneic Oligodendrocyte Progenitors in Dysmyelinated Mice Intrathecal Methotrexate Treatment in Multiple Sclerosis Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis JCV detection in multiple sclerosis patients treated with natalizumab Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making Specific electron transport chain abnormalities in amyotrophic lateral sclerosis Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus CCL genes in multiple sclerosis and systemic lupus erythematosus Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity Long-term intrathecal baclofen therapy in ambulatory patients with spasticity IN THIS SECTION What is MS? History of Tisch MSRCNY Dr. Saud A. Sadiq Principal Scientists Research Center Team Board of Directors Financials and Disclosures Education & Training Careers Tisch MS Research Center of New York 521 West 57th Street 4th Floor New York, NY 10019 (646) 557-3900 Privacy Policy Tisch MS News Tisch MSRCNY Holiday Closing Research Priorities at Tisch MSRCNY Happy Veterans Day! More » Support Tisch MS Support Tisch MS and our innovative research leading to treatments that improve the lives of patients. DONATE Safe & Secure This is the website of the Tisch MS Research Center of New York, a non-profit, 501(c)(3), independent, multiple sclerosis research center, and not a medical practice. CLICK HERE to be directed to our clinical affiliate, the International Multiple Sclerosis Management Practice. 521 West 57 St., 4th Flr, NY, NY 10019 | ©2017 Tisch MS All rights reserved. We use cookies on this site to enhance your user experience By clicking the Accept button, you agree to us doing so. No, give me more info OK, I agree